Teleflex Inc. (TFX) Receives Consensus Rating of “Buy” from Brokerages
Shares of Teleflex Inc. (NYSE:TFX) have been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the stock. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $173.38.
A number of research firms recently weighed in on TFX. Leerink Swann boosted their price target on shares of Teleflex from $183.00 to $190.00 and gave the stock a “market perform” rating in a research note on Friday, July 29th. Jefferies Group boosted their price target on shares of Teleflex from $157.00 to $185.00 and gave the stock a “hold” rating in a research note on Friday, July 29th. Barclays PLC boosted their price target on shares of Teleflex from $183.00 to $185.00 and gave the stock an “overweight” rating in a research note on Friday, July 29th. Finally, Zacks Investment Research raised shares of Teleflex from a “hold” rating to a “buy” rating and set a $192.00 price target for the company in a research note on Wednesday, June 29th.
Teleflex (NYSE:TFX) traded up 0.77% during mid-day trading on Thursday, hitting $166.64. The stock had a trading volume of 103,450 shares. The firm’s 50-day moving average is $175.50 and its 200 day moving average is $170.45. The stock has a market cap of $7.34 billion, a PE ratio of 29.58 and a beta of 0.83. Teleflex has a one year low of $123.79 and a one year high of $188.79.
Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, July 28th. The medical technology company reported $1.89 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.74 by $0.15. The business earned $473.60 million during the quarter, compared to the consensus estimate of $468.40 million. Teleflex had a net margin of 14.89% and a return on equity of 15.59%. Teleflex’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.42 earnings per share. Equities research analysts expect that Teleflex will post $7.33 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 15th. Stockholders of record on Monday, August 15th were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.82%. The ex-dividend date of this dividend was Thursday, August 11th. Teleflex’s dividend payout ratio (DPR) is presently 24.11%.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TFX. HBK Investments L P bought a new position in Teleflex during the first quarter valued at $879,000. Wellington Management Group LLP boosted its position in Teleflex by 120.7% in the first quarter. Wellington Management Group LLP now owns 761,800 shares of the medical technology company’s stock valued at $119,610,000 after buying an additional 416,696 shares during the period. Geode Capital Management LLC boosted its position in Teleflex by 2.3% in the first quarter. Geode Capital Management LLC now owns 257,849 shares of the medical technology company’s stock valued at $40,484,000 after buying an additional 5,796 shares during the period. Kimelman & Baird LLC boosted its position in Teleflex by 1.8% in the first quarter. Kimelman & Baird LLC now owns 155,609 shares of the medical technology company’s stock valued at $24,432,000 after buying an additional 2,679 shares during the period. Finally, State Street Corp boosted its position in Teleflex by 0.5% in the first quarter. State Street Corp now owns 1,091,317 shares of the medical technology company’s stock valued at $171,347,000 after buying an additional 5,130 shares during the period. Institutional investors own 93.77% of the company’s stock.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company markets and sells its products to hospitals and healthcare providers, across the world, through a combination of its direct sales force and distributors.
Receive News & Stock Ratings for Teleflex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Inc. and related stocks with our FREE daily email newsletter.